About US
Contact us
-
FDA greenlights Stealth Bio's injection as 1st treatment for Barth syndromeAfter a tumultuous journey filled with delays and rejection, the FDA has approved Stealth BioTherapeutics’ treatment for the ultrarare disease Barth syndrome, marking the peptide as the first therapy2025/9/18
-
Novo Nordisk pads case for Wegovy in a pill as oral obesity asset nears FDA decisionThe duel of the GLP-1 data sets continues this week, with Novo issuing the latest salvo of updates on its oral obesity candidate and an Ozempic head-to-head trial win against another stalwart diabete2025/9/18
-
AstraZeneca's Fasenra comes up short again in COPD as injectable Saphnelo makes grade in lupusAfter another swing and a miss for AstraZeneca's Fasenra in chronic obstructive pulmonary disease (COPD), the company is pivoting to other options in its portfolio that might have potential to treat2025/9/16
-
In New Jersey, Novo Nordisk cuts 263 workers while BMS slashes 282 rolesNovo Nordisk is not wasting time beginning the layoffs itannouncedlast week as part of a major restructuring effort. The Danish company is dismissing 263 employees from its U.S. headquarters in Plain2025/9/16
-
SK's blockbuster hopeful Xcopri reduces seizures in phase 3 trial, teeing up FDA expansion bidSK Biopharmaceutical’s Xcopri (cenobamate) met the bar in a phase 3 trial that could support the company’s ambitions of building a blockbuster with an expansion into another seizures subtype. The Sou2025/9/11
-
GSK joins US investment spree with $30B planned for manufacturing, R&DBritish Big Pharma GSK is welcoming President Donald Trump to the U.K. with a hefty gift: a five-year, $30 billion planned investment in U.S. R&D and manufacturing. The funds are set to be spread2025/9/11
-
HHS taps 5 new members for CDC vaccine panel ahead of this week's meetingAfter Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. overhauled the Centers for Disease Control and Prevention's (CDC's) vaccine advisory panel over the summer, replaci2025/9/9
-
AGC Biologics telegraphs 278 layoffs as it plots sale of Colorado manufacturing plantsAs AGC Biologics looks to recalibrate its CDMO business, the Seattle-based manufacturer is planning to part ways with a pair of facilities in Colorado. AGC has started a “structured process” to seek2025/9/9
-
Corstasis scores FDA nod for nasal spray treatment, touts sales potentialForty-two years after approving the potent diuretic Bumex (bumetanide) as both an oral and infused treatment for edema, the FDA has endorsed a new version of the drug to be delivered as a nasal spray2025/9/3
-
BMS sells controlling stake in historic US-China pharmaceutical joint ventureMore than 40 years after establishing the first U.S. pharmaceutical joint venture in China, Bristol Myers Squibb is handing over its controlling stake in the business. BMS has inked an agreement to s2025/9/3